Identification

Name
Bromfenac
Accession Number
DB00963  (APRD00831)
Type
Small Molecule
Groups
Approved
Description

Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool to optimize surgical outcomes.

Structure
Thumb
Synonyms
  • [2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid
  • 2-amino-3-(4-Bromobenzoyl)benzeneacetic acid
  • Bromfenaco
  • Bromfenacum
External IDs
ISV-303
Product Ingredients
IngredientUNIICASInChI Key
Bromfenac sodium8ECV571Y37120638-55-3PPOSVVJOVKVBPW-UHFFFAOYSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BromdaySolution / drops.9 mg/mLOphthalmicIsta Pharmaceuticals, Inc2010-09-202018-01-25Us
BromdaySolution / drops.9 mg/mLOphthalmicPhysicians Total Care, Inc.2011-09-30Not applicableUs
BromdaySolution / drops.9 mg/mLOphthalmicUnit Dose Services2010-09-20Not applicableUs
BromSite 0.075%Solution / drops.76 mg/mLOphthalmicSun Pharmaceutical Industries Limited2016-05-01Not applicableUs
ProlensaSolution0.07 %OphthalmicBausch & Lomb Inc2015-09-25Not applicableCanada
ProlensaSolution / drops.7 mg/mLOphthalmicBauch & Lomb Incorporated2013-04-05Not applicableUs
YelloxSolution / drops0.9 mg/mlOphthalmicPharma Swiss Ceska Republika S.R.O2011-05-18Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BromfenacSolution / drops1.035 mg/mLOphthalmicHi Tech Pharmacal Co., Inc.2014-01-22Not applicableUs
BromfenacSolution / drops.9 mg/mLOphthalmicMylan Pharmaceuticals2011-05-112017-12-22Us
BromfenacSolution / drops.9 mg/mLOphthalmicMylan Pharmaceuticals2011-05-112017-12-22Us
BromfenacSolution / drops1.035 mg/mLOphthalmicPhysicians Total Care, Inc.2012-04-13Not applicableUs
BromfenacSolution / drops.9 mg/mLOphthalmicMylan Pharmaceuticals2011-05-112017-12-22Us
BromfenacSolution / drops.9 mg/mLOphthalmicApotex Corporation2014-06-192018-01-23Us
Bromfenac Ophthalmic Solution, 0.09%Solution / drops1.035 mg/mLOphthalmicApotex Corporation2014-06-232018-01-23Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Pred Phos - BromBromfenac sodium (.75 mg/mL) + Prednisolone sodium phosphate (10 mg/mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-07-02Not applicableUs
Pred Phos-Gati-BromBromfenac (.75 mg/mL) + Gatifloxacin (5 mg/mL) + Prednisolone sodium phosphate (10 mg/mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-07-02Not applicableUs
Pred-BromBromfenac sodium (.75 mg/mL) + Prednisolone acetate (10 mg/mL)Suspension / dropsOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
Pred-BromBromfenac (.75 mg/mL) + Prednisolone acetate (10 mg/mL)Suspension / dropsOphthalmicImprimis Rx Nj2018-02-01Not applicableUs
Pred-Gati-BromBromfenac (.75 mg/mL) + Gatifloxacin (5 mg/mL) + Prednisolone acetate (10 mg/mL)Suspension / dropsOphthalmicImprims Njof, Llc2018-01-05Not applicableUs
Pred-Gati-BromBromfenac (.75 mg/mL) + Gatifloxacin hemihydrate (5 mg/mL) + Prednisolone acetate (10 mg/mL)Suspension / dropsOphthalmicImprimis Rx Nj2018-01-01Not applicableUs
Pred-Gati-BromBromfenac sodium (.75 mg/mL) + Gatifloxacin (5 mg/mL) + Prednisolone acetate (10 mg/mL)Suspension / dropsOphthalmicImprimis Njof, Llc2018-01-12Not applicableUs
International/Other Brands
Duract (Wyeth-Ayerst) / Xibrom (ISTA Pharmaceuticals)
Categories
UNII
864P0921DW
CAS number
91714-94-2
Weight
Average: 334.165
Monoisotopic: 333.000055902
Chemical Formula
C15H12BrNO3
InChI Key
ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
InChI
InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
IUPAC Name
2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
SMILES
NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1

Pharmacology

Indication

For the treatment of postoperative inflammation in patients who have undergone cataract extraction.

Associated Conditions
Pharmacodynamics

Bromfenac ophthalmic solution is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use.

Mechanism of action

The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption

The plasma concentration of bromfenac following ocular administration in humans is unknown.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bromfenac Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Bromfenac.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Bromfenac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Bromfenac is combined with 5-androstenedione.Experimental, Illicit
AbciximabBromfenac may increase the anticoagulant activities of Abciximab.Approved
AcebutololBromfenac may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolBromfenac may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Bromfenac.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Bromfenac.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Bromfenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alendronic acid.Approved
AliskirenBromfenac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Bromfenac.Experimental
AlprenololBromfenac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Bromfenac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Amcinonide.Approved
AmikacinBromfenac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideBromfenac may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Bromfenac.Approved
AncrodBromfenac may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Bromfenac.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Bromfenac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Bromfenac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bromfenac.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Antipyrine.Approved, Investigational
Antithrombin III humanBromfenac may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Antrafenine.Approved
ApixabanBromfenac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Bromfenac.Investigational
ApramycinBromfenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Bromfenac.Approved, Investigational
ArbekacinBromfenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinBromfenac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBromfenac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBromfenac may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineBromfenac may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Atamestane.Investigational
AtenololBromfenac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Bromfenac.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Bromfenac.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bromfenac.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Bromfenac.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Bromfenac is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Balsalazide.Approved, Investigational
BazedoxifeneBromfenac may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminBromfenac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Bromfenac.Approved, Investigational
BefunololBromfenac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinBromfenac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Bromfenac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bromfenac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Bromfenac.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Bromfenac.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Bromfenac.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Bromfenac.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Bromfenac.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bromfenac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Betamethasone.Approved, Vet Approved
BetaxololBromfenac may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Bromfenac.Approved, Investigational
BevantololBromfenac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Bromfenac.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Bromfenac.Approved, Investigational
BisoprololBromfenac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBromfenac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololBromfenac may decrease the antihypertensive activities of Bopindolol.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Bromfenac.Investigational
BucindololBromfenac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Bromfenac.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Bufexamac.Approved, Experimental
BufuralolBromfenac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Bromfenac.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Bromfenac.Approved
BupranololBromfenac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bromfenac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Bromfenac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Bromfenac.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Bromfenac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololBromfenac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBromfenac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Bromfenac.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Celecoxib.Approved, Investigational
CeliprololBromfenac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinBromfenac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Bromfenac.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bromfenac.Approved, Vet Approved
ChlorotrianiseneBromfenac may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Bromfenac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cimicoxib.Investigational
CinoxacinBromfenac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinBromfenac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Bromfenac.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Bromfenac.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Bromfenac.Vet Approved
CloranololBromfenac may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneBromfenac may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensBromfenac may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Bromfenac.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bromfenac.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Bromfenac is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateBromfenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinBromfenac may increase the thrombogenic activities of Daidzein.Experimental
DalteparinBromfenac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBromfenac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Bromfenac.Investigational
DarexabanBromfenac may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Bromfenac is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Bromfenac is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Delapril.Investigational
DesipramineBromfenac may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinBromfenac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Bromfenac.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Bromfenac.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bromfenac.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Bromfenac.Experimental
DextranBromfenac may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinBromfenac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Bromfenac is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bromfenac.Approved, Vet Approved
DicoumarolBromfenac may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolBromfenac may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolBromfenac may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Bromfenac.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Bromfenac is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bromfenac.Approved
DihydrostreptomycinBromfenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Bromfenac.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Bromfenac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Bromfenac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Bromfenac.Approved
DiphenadioneBromfenac may increase the anticoagulant activities of Diphenadione.Experimental
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Bromfenac.Approved
DrospirenoneBromfenac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Bromfenac.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Bromfenac.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Bromfenac.Investigational
Edetic AcidBromfenac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBromfenac may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Bromfenac.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Bromfenac is combined with Enalaprilat.Approved
EnoxacinBromfenac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinBromfenac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Bromfenac.Experimental
EpanololBromfenac may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolBromfenac may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Bromfenac.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Bromfenac.Experimental
EplerenoneBromfenac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bromfenac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bromfenac.Approved
EquileninThe risk or severity of adverse effects can be increased when Bromfenac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Equilin.Approved
EquolBromfenac may increase the thrombogenic activities of Equol.Investigational
EsatenololBromfenac may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Bromfenac.Approved, Investigational
EsmololBromfenac may decrease the antihypertensive activities of Esmolol.Approved
EstradiolBromfenac may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateBromfenac may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateBromfenac may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateBromfenac may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolBromfenac may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedBromfenac may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bromfenac.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Bromfenac.Experimental
Ethinyl EstradiolBromfenac may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateBromfenac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Bromfenac.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Bromfenac.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Bromfenac.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Bromfenac.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Bromfenac.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Bromfenac.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Bromfenac.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Bromfenac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Bromfenac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Bromfenac.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Bromfenac.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bromfenac.Approved, Investigational
FleroxacinBromfenac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bromfenac.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fludrocortisone.Approved, Investigational
FluindioneBromfenac may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineBromfenac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Bromfenac.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Bromfenac.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Bromfenac.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Bromfenac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bromfenac.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Bromfenac.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Bromfenac.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bromfenac.Approved, Nutraceutical, Vet Approved
FondaparinuxBromfenac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Bromfenac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fosinopril.Approved
FramycetinBromfenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Bromfenac.Approved, Vet Approved
GabexateBromfenac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBromfenac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBromfenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Bromfenac.Approved, Withdrawn
GemifloxacinBromfenac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBromfenac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinBromfenac may increase the thrombogenic activities of Genistein.Investigational
GentamicinBromfenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABromfenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Bromfenac.Approved, Investigational
GrepafloxacinBromfenac may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Bromfenac.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Bromfenac.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Bromfenac is combined with HE3286.Investigational
HeparinBromfenac may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolBromfenac may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Bromfenac.Investigational
HydralazineBromfenac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bromfenac.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Bromfenac.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Bromfenac.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bromfenac.Approved, Investigational
Hygromycin BBromfenac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Bromfenac.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Bromfenac.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Bromfenac is combined with Icosapent.Approved, Nutraceutical
IdraparinuxBromfenac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bromfenac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Bromfenac.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Bromfenac.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bromfenac.Approved
IndenololBromfenac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Bromfenac.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Bromfenac.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bromfenac.Approved, Investigational
IsepamicinBromfenac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bromfenac.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Bromfenac.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Bromfenac is combined with Istaroxime.Investigational
KanamycinBromfenac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Bromfenac.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Bromfenac.Approved
LabetalolBromfenac may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Bromfenac.Approved, Investigational
LandiololBromfenac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bromfenac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Bromfenac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Bromfenac.Approved, Investigational
LepirudinBromfenac may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Bromfenac.Approved, Investigational
LetaxabanBromfenac may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololBromfenac may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololBromfenac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBromfenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Bromfenac.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Bromfenac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Bromfenac.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Bromfenac.Experimental
LomefloxacinBromfenac may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Bromfenac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Bromfenac.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bromfenac.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Bromfenac.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Bromfenac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Bromfenac.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bromfenac.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Bromfenac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mefenamic acid.Approved
MelagatranBromfenac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Meloxicam.Approved, Vet Approved
MepindololBromfenac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mesalazine.Approved
MestranolBromfenac may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Bromfenac.Approved, Investigational, Withdrawn
MethallenestrilBromfenac may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bromfenac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bromfenac.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Bromfenac.Approved, Vet Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Bromfenac.Approved, Vet Approved
MetipranololBromfenac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac.Approved
MetoprololBromfenac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Bromfenac.Investigational, Withdrawn
MicronomicinBromfenac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Bromfenac.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Bromfenac.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Bromfenac.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bromfenac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bromfenac.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Bromfenac.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bromfenac.Approved
MoxestrolBromfenac may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinBromfenac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bromfenac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bromfenac.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nabumetone.Approved
NadololBromfenac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinBromfenac may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Bromfenac.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bromfenac.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Bromfenac.Investigational
Nalidixic AcidBromfenac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Bromfenac is combined with NCX 1022.Investigational
NeamineBromfenac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololBromfenac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Bromfenac.Approved, Withdrawn
NemonoxacinBromfenac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Bromfenac is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nepafenac.Approved, Investigational
NetilmicinBromfenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Bromfenac.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Bromfenac.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Bromfenac.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Bromfenac.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Bromfenac.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Bromfenac.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Bromfenac.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Bromfenac.Investigational
NorfloxacinBromfenac may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinBromfenac may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bromfenac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bromfenac.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bromfenac.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Bromfenac is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Bromfenac is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Bromfenac.Vet Approved
OtamixabanBromfenac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxaprozin.Approved
Oxolinic acidBromfenac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololBromfenac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bromfenac.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Bromfenac.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Parecoxib.Approved
ParomomycinBromfenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Bromfenac.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Bromfenac.Approved, Investigational
PazufloxacinBromfenac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBromfenac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBromfenac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateBromfenac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateBromfenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Perindopril.Approved
PhenindioneBromfenac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonBromfenac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bromfenac.Approved, Investigational
PindololBromfenac may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidBromfenac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bromfenac.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Bromfenac.Approved, Investigational
Piromidic acidBromfenac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Bromfenac.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorBromfenac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinBromfenac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateBromfenac may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bromfenac.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pomalidomide.Approved
Potassium CitrateBromfenac may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololBromfenac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Bromfenac.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Bromfenac.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Bromfenac can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Bromfenac.Experimental
PromestrieneBromfenac may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Bromfenac.Approved, Investigational
PropafenoneBromfenac may decrease the antihypertensive activities of Propafenone.Approved
PropranololBromfenac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Bromfenac.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Bromfenac.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Bromfenac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Bromfenac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Bromfenac.Vet Approved
Protein CBromfenac may increase the anticoagulant activities of Protein C.Approved
Protein S humanBromfenac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBromfenac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBromfenac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Bromfenac.Investigational
PuromycinBromfenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Quinapril.Approved, Investigational
QuinestrolBromfenac may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bromfenac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinBromfenac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinBromfenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Risedronate.Approved, Investigational
RivaroxabanBromfenac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinBromfenac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinBromfenac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Bromfenac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bromfenac.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bromfenac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Bromfenac.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Bromfenac.Approved, Investigational
SecoisolariciresinolBromfenac may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Bromfenac.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Bromfenac.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Bromfenac.Investigational
SertralineSertraline may increase the antiplatelet activities of Bromfenac.Approved
SisomicinBromfenac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinBromfenac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Bromfenac is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Bromfenac.Approved
SotalolBromfenac may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinBromfenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bromfenac is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Bromfenac.Investigational
StreptomycinBromfenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Sulindac.Approved, Investigational
SulodexideBromfenac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Bromfenac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Bromfenac.Experimental
Synthetic Conjugated Estrogens, ABromfenac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BBromfenac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusBromfenac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Bromfenac.Approved
TalinololBromfenac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Bromfenac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Bromfenac.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Bromfenac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bromfenac.Approved, Investigational
TemafloxacinBromfenac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Bromfenac.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Bromfenac.Vet Approved
TerbutalineBromfenac may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Bromfenac.Approved
TertatololBromfenac may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Bromfenac.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiaprofenic acid.Approved
TiboloneBromfenac may increase the thrombogenic activities of Tibolone.Approved, Investigational
Tiludronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololBromfenac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Bromfenac.Investigational
TioclomarolBromfenac may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tixocortol.Approved, Withdrawn
TobramycinBromfenac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Bromfenac.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bromfenac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bromfenac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBromfenac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Bromfenac.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Bromfenac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Bromfenac.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Trolamine salicylate.Approved
TrovafloxacinBromfenac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinBromfenac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bromfenac.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bromfenac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Bromfenac.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Bromfenac.Approved
WarfarinBromfenac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBromfenac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Bromfenac.Approved, Investigational
ZeranolBromfenac may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Bromfenac.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Bromfenac.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bromfenac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Shirou Sawa, "Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac." U.S. Patent US20070082857, issued April 12, 2007.

US20070082857
General References
Not Available
External Links
Human Metabolome Database
HMDB0015098
PubChem Compound
60726
PubChem Substance
46508121
ChemSpider
54730
ChEBI
240107
ChEMBL
CHEMBL1077
Therapeutic Targets Database
DAP000732
PharmGKB
PA448670
HET
27R
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bromfenac
ATC Codes
S01BC11 — Bromfenac
AHFS Codes
  • 52:08.20 — Nonsteroidal Anti-inflammatory Agents
PDB Entries
4mjq
FDA label
Download (41.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Unknown StatusTreatmentDiabetic Macular Edema (DME)1
1, 2CompletedTreatmentCataracts / Ocular inflammatory conditions / Pain1
2CompletedTreatmentCataract operation1
2CompletedTreatmentCataracts1
2WithdrawnNot AvailableCystoid Macular Edema1
3CompletedPreventionCataracts / Cystoid Macular Edema / Diabetes Mellitus (DM)1
3CompletedTreatmentCataracts2
3CompletedTreatmentCataracts / Inflammatory Reaction / Pain1
3CompletedTreatmentCataracts / Postoperative Complications1
3CompletedTreatmentCataracts / Ocular inflammatory conditions2
3CompletedTreatmentConjunctivitis, Seasonal Allergic1
3CompletedTreatmentInflammatory Reaction / Pain2
3CompletedTreatmentOcular inflammatory conditions1
4Active Not RecruitingTreatmentInflammation Eye1
4CompletedNot AvailableMyopia1
4CompletedPreventionCystoid Macular Edema / Retinal Thickening1
4CompletedTreatmentAcute Pseudophakic Cystoid Macular Edema1
4CompletedTreatmentCataracts5
4CompletedTreatmentCataracts / Pseudoexfoliation Syndrome1
4CompletedTreatmentDiabetic Macular Edema (DME)1
4CompletedTreatmentDry Eye Syndrome (DES) / Ocular Comfort1
4CompletedTreatmentInflammatory Reaction / Pseudophakia1
4CompletedTreatmentIntraocular Pressure1
4CompletedTreatmentPost Operative Anterior Chamber Inflammation (Flare)1
4RecruitingPreventionCataracts1
4RecruitingTreatmentOcular inflammatory conditions / Ocular Pain / Post-surgical Inflammation / Pterygium1
Not AvailableCompletedTreatmentCataracts1
Not AvailableRecruitingTreatmentCataracts / Inflammatory Reaction / Retinal Edema1

Pharmacoeconomics

Manufacturers
  • Ista pharmaceuticals
Packagers
  • Bausch & Lomb Inc.
  • ISTA Pharmaceuticals
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic.9 mg/mL
Solution / dropsOphthalmic1.035 mg/mL
Solution / dropsOphthalmic.76 mg/mL
Solution / dropsOphthalmic
Suspension / dropsOphthalmic
SolutionOphthalmic0.07 %
Solution / dropsOphthalmic.7 mg/mL
Solution / dropsOphthalmic0.9 mg/ml
Prices
Unit descriptionCostUnit
Xibrom 0.09% Solution 5ml Bottle289.59USD bottle
Xibrom 0.09% Solution 2.5ml Bottle148.56USD bottle
Xibrom 0.09% eye drops68.57USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8927606No2004-01-162024-01-16Us
US8871813No2004-01-162024-01-16Us
US8129431No2005-09-112025-09-11Us
US9144609No2004-01-162024-01-16Us
US8669290No2004-01-162024-01-16Us
US8754131No2004-01-162024-01-16Us
US8778999No2009-09-032029-09-03Us
US9517220No2013-11-112033-11-11Us
US9561277No2004-01-162024-01-16Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0126 mg/mLALOGPS
logP3ALOGPS
logP3.66ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)3.81ChemAxon
pKa (Strongest Basic)1.59ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80.39 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity80.26 m3·mol-1ChemAxon
Polarizability29.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9133
Blood Brain Barrier+0.8403
Caco-2 permeable+0.5999
P-glycoprotein substrateNon-substrate0.7803
P-glycoprotein inhibitor INon-inhibitor0.663
P-glycoprotein inhibitor IINon-inhibitor0.8983
Renal organic cation transporterNon-inhibitor0.921
CYP450 2C9 substrateNon-substrate0.8624
CYP450 2D6 substrateNon-substrate0.898
CYP450 3A4 substrateNon-substrate0.7483
CYP450 1A2 substrateNon-inhibitor0.7326
CYP450 2C9 inhibitorNon-inhibitor0.6515
CYP450 2D6 inhibitorNon-inhibitor0.9003
CYP450 2C19 inhibitorNon-inhibitor0.8688
CYP450 3A4 inhibitorNon-inhibitor0.8927
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7996
Ames testNon AMES toxic0.88
CarcinogenicityNon-carcinogens0.7301
BiodegradationNot ready biodegradable0.9618
Rat acute toxicity2.5564 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9747
hERG inhibition (predictor II)Non-inhibitor0.8313
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzophenones
Direct Parent
Benzophenones
Alternative Parents
Diphenylmethanes / Aryl-phenylketones / Benzoyl derivatives / Aniline and substituted anilines / Bromobenzenes / Aryl bromides / Vinylogous amides / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids
show 5 more
Substituents
Benzophenone / Diphenylmethane / Aryl-phenylketone / Benzoyl / Aryl ketone / Aniline or substituted anilines / Bromobenzene / Halobenzene / Aryl bromide / Aryl halide
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organobromine compound, benzophenones, substituted aniline, aromatic amino acid (CHEBI:240107)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [PubMed:16846546]
  2. Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S: Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32. [PubMed:16982289]
  3. Chitturi S, George J: Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis. 2002;22(2):169-83. [PubMed:12016548]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [PubMed:16846546]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Cho H, Wolf KJ, Wolf EJ: Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol. 2009;3:199-210. Epub 2009 Jun 2. [PubMed:19668566]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:32